Welcome to our dedicated page for Synergy CHC SEC filings (Ticker: SNYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synergy CHC Corp. (NASDAQ: SNYR) SEC filings page brings together the company’s official disclosures as a smaller reporting company in the consumer health and wellness sector. Synergy develops and markets branded products such as FOCUSfactor® brain-health supplements and functional beverages and Flat Tummy® women’s wellness offerings, and its regulatory filings provide detailed insight into how this business is structured and financed.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Synergy reports product sales, license revenue, gross profit, operating expenses, operating income, net income, and non‑GAAP measures like EBITDA and Adjusted EBITDA. These filings also describe working capital, inventory levels, debt obligations, and stockholders’ equity or deficit, giving investors a view of how the company funds expansion of its FOCUSfactor® and Flat Tummy® brands.
Current reports on Form 8‑K document material events such as quarterly earnings releases, public offerings of common stock, changes to equity incentive plans, authorization of preferred stock, and board or executive changes. For example, Synergy has used Form 8‑K to report an underwritten public offering of common stock, amendments to its 2024 Equity Incentive Plan, authorization of preferred stock, and governance updates including director appointments and role transitions.
Registration statements such as the Form S‑1 provide additional background on the company’s business, risk factors, use of proceeds, capital structure, and status as a smaller reporting company. Investors interested in ownership changes and executive incentives can review equity plan amendments and related disclosures within these filings. On this page, AI-powered tools can help summarize lengthy documents, highlight key financial and governance changes, and make complex sections of 10‑K, 10‑Q, 8‑K, and S‑1 filings easier to understand.
Use this filings hub to track Synergy CHC Corp.’s official financial reporting, capital raises, governance actions, and other regulatory disclosures that shape the outlook for SNYR stock.
Synergy CHC Corp. reported that on August 11, 2026 it received a notice of default from ACP Agency, LLC under its Term Loan Credit Agreement dated May 30, 2025. ACP asserted an Event of Default occurred after Synergy failed to make the interest payment due on August 3, 2026, following expiration of the cure period on August 6, 2026. ACP also stated that the forbearance period under a Forbearance Agreement dated May 28, 2026 terminated on August 6, 2026 and that a forbearance fee of $404,173.06 is now payable. Approximately $17.6 million principal remains outstanding under the Credit Agreement, excluding accrued interest, fees and expenses. ACP has reserved all rights and remedies, including charging interest at a post-default rate and accelerating the loan obligations.
Synergy CHC Corp. reports that on July 15, 2026, Costco Wholesale Corporation informed the company it will discontinue carrying Synergy’s FOCUSfactor products. Costco has been a significant customer for more than 16 years and accounted for approximately 58% of net revenue for the fiscal year ended December 31, 2025.
The company expects Costco’s decision to have a material adverse effect on its business, results of operations, liquidity and financial condition, and is evaluating available financing and other strategic alternatives in response.
Synergy CHC Corp. director and president Alfred Baumeler re-priced a stock option award covering 150,000 shares of common stock. On this Form 4, a prior option for 150,000 shares with a $2.38 per share exercise price was canceled and a new option for 150,000 shares with a $0.21 per share exercise price was granted in its place.
According to the footnotes, this reduction in exercise price is treated under Section 16 as a cancellation and re-grant of the same award. The new option vests on the same schedule as the original option, with one-third vesting on the first anniversary of September 18, 2025 and the remaining two-thirds vesting in equal monthly installments over the following 24 months, subject to continued service. The new option expires on the five-year anniversary of the original grant date. These are compensation-related derivative transactions, with no reported open-market purchases or sales of common shares.
Synergy CHC Corp. Chief Financial Officer Jaime Fickett reported a restructuring of an existing stock option award. An original option covering 150,000 shares of common stock with a $2.38 exercise price was deemed canceled for Section 16 purposes, and a new option for 150,000 shares was granted with a reduced exercise price of $0.21 per share.
According to the footnotes, this reduction in exercise price is treated as a material modification, with the new option keeping the same vesting schedule and a five-year term from the original September 18, 2025 grant date. One-third of the option vests on the first anniversary of that date, and the remaining two-thirds vest in equal monthly installments over the following 24 months, subject to continued service.
Synergy CHC Corp. insider activity shows an option repricing for shares held indirectly through Kenek Brands Inc., which is controlled by CEO and Chairman Ross Jack. A stock option for 750,000 shares of common stock with a $2.38 exercise price was deemed canceled and disposed of back to the company.
On the same date, Kenek Brands Inc. received a new stock option covering 750,000 underlying shares at a reduced exercise price of $0.21 per share. The new option keeps the original vesting schedule tied to the September 18, 2025 grant date and expires on the five-year anniversary of that date. The filing notes Jack’s indirect beneficial ownership through Kenek Brands Inc., with beneficial ownership disclaimed except for his pecuniary interest.
Synergy CHC Corp. reported the results of its 2026 annual stockholder meeting. Stockholders approved amending the 2024 Equity Incentive Plan to increase the pool to 150,000,000 common shares and allow repricing of outstanding awards. They also authorized the board to implement one or more reverse stock splits with an aggregate ratio up to 1‑for‑200.
Investors ratified RBSM LLP as auditor for the 2026 fiscal year, approved the full issuance of shares underlying a Lender Warrant under Nasdaq rules, and elected five directors to serve until the 2027 annual meeting. On the April 24, 2026 record date, 14,899,883 common shares were outstanding, with about 65% of votes represented at the meeting.
Synergy CHC Corp. received a non-compliance notice from Nasdaq after its common stock closed below $1.00 per share for 30 consecutive business days, violating the Nasdaq Capital Market minimum bid price rule.
The company has 180 calendar days, until November 11, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days. If it meets other Nasdaq listing standards, it may qualify for an additional 180-day grace period. Failing to regain compliance could lead to delisting, and management is monitoring the share price and may consider options such as a reverse stock split.
Synergy CHC Corp. is registering 101,710,000 shares of common stock for resale by Hudson Global Ventures, LLC under a Form S-1. The registered shares consist of 100,000,000 equity line (ELOC) shares, 1,540,000 warrant shares and 170,000 existing shares issued for prior consulting services.
The company will not receive proceeds from the selling stockholder’s resales, but may raise up to $36,000,000 over about 24 months by selling ELOC shares directly to Hudson under an Equity Purchase Agreement. As of May 14, 2026, 14,899,883 shares of common stock were outstanding, and the last reported Nasdaq price was $0.30 per share.
The filing also highlights Synergy’s nutraceutical brands FOCUSfactor and Flat Tummy, with 2025 revenue of $30.4 million, net loss of $(12.3) million and EBITDA of $(6.2) million, compared with 2024 revenue of $34.8 million, net income of $2.1 million and EBITDA of $6.5 million. Management attributes 2025 pressures partly to bad-debt and inventory write-offs.
Synergy CHC Corp. reported weaker results for the quarter ended March 31, 2026. Revenue fell to $5.49 million from $8.17 million a year earlier as prior-year license revenue of $1.5 million did not repeat and online sales were hurt by out-of-stock issues in the Flat Tummy brand.
Despite over $650,000 in functional beverage revenue and an estimated beverage annual run rate above $4 million, profitability deteriorated. The company posted an operating loss of $0.57 million, a net loss of $2.57 million, and a basic and diluted loss per share of $0.23, versus net income of $0.88 million and earnings per share of $0.10 in the prior-year quarter.
Cash and cash equivalents declined to about $0.30 million as of March 31, 2026 from $2.6 million at December 31, 2025, and the company moved to a working capital deficit of $0.50 million. Total liabilities were $31.87 million against a stockholders’ deficit of $25.41 million. After quarter-end, Synergy raised approximately $2.7 million in gross proceeds through an at-the-market equity program to bolster liquidity.